Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avillion LLP
The ABV 8 fund will invest $15m to $30m per company across the range from start-ups to development-stage companies.
Novartis has added an anti-osteoarthritic Nanobody, M6495, to its growing pipeline of candidates for the condition, in a €450m agreement with Merck KGaA that sees the latter deliver on its plans to find new homes for its osteoarthritis pipeline.
Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.
The German major is looking for a partner to advance its IL-17A/IL-17F nanobody sonelokinab for psoriasis but the search could be tricky given the strength of Novartis's Cosentyx and Eli Lilly's Taltz, while UCB's IL-17A and IL-17F inhibitor bimekizumab is likely to be approved soon.
- Other Names / Subsidiaries
- Avillion Group
- Bond Avillion 2 Development LP